HR+/HER2- Early Breast Cancer research hub

Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

This study looks at how well women with a certain type of early breast cancer (HR+/HER2-) continue taking their abemaciclib medicine. Researchers are checking records to see how many take it for at least 6 months after starting.